Skip to main content
Top
Published in: Journal of Urban Health 1/2007

01-01-2007

Physicians’ Knowledge of and Willingness to Prescribe Naloxone to Reverse Accidental Opiate Overdose: Challenges and Opportunities

Authors: Leo Beletsky, Robin Ruthazer, Grace E. Macalino, Josiah D. Rich, Litjen Tan, Scott Burris

Published in: Journal of Urban Health | Issue 1/2007

Login to get access

Abstract

Naloxone, the standard treatment for heroin overdose, is a safe and effective prescription drug commonly administered by emergency room physicians or first responders acting under standing orders of physicians. High rates of overdose deaths and widely accepted evidence that witnesses of heroin overdose are often unwilling or unable to call 9-1-1 has led to interventions in several US cities and abroad in which drug users are instructed in overdose rescue techniques and provided a “take-home” dose of naloxone. Under current Food and Drug Administration (FDA) regulations, such interventions require physician involvement. As part of a larger study to evaluate the knowledge and attitudes of doctors towards providing drug treatment and harm reduction services to injection drug users (IDUs), we investigated physician knowledge and willingness to prescribe naloxone. Less than one in four of the respondents in our sample reported having heard of naloxone prescription as an intervention to prevent opiate overdose, and the majority reported that they would never consider prescribing the agent and explaining its application to a patient. Factors predicting a favorable attitude towards prescribing naloxone included fewer negative perceptions of IDUs, assigning less importance to peer and community pressure not to treat IDUs, and increased confidence in ability to provide meaningful treatment to IDUs. Our data suggest that steps to promote naloxone distribution programs should include physician education about evidence-based harm minimization schemes, broader support for such initiatives by professional organizations, and policy reform to alleviate medicolegal concerns associated with naloxone prescription. FDA re-classification of naloxone for over-the-counter sales and promotion of nasal-delivery mechanism for this agent should be explored.
Literature
1.
go back to reference Zule W. Risk and reciprocity: HIV and the injection drug user. J Psychoact Drugs. 1992;24:242–249. Zule W. Risk and reciprocity: HIV and the injection drug user. J Psychoact Drugs. 1992;24:242–249.
3.
4.
go back to reference Warner-Smith M, Darke S, Lynskey M, Hall W. Heroin overdose: causes and consequences. Addiction. 2001;96(8):1113–1125.PubMedCrossRef Warner-Smith M, Darke S, Lynskey M, Hall W. Heroin overdose: causes and consequences. Addiction. 2001;96(8):1113–1125.PubMedCrossRef
5.
go back to reference Warner-Smith M, Darke S, Day C. Morbidity associated with non-fatal heroin overdose. Addiction. 2002;97(8):963–967.PubMedCrossRef Warner-Smith M, Darke S, Day C. Morbidity associated with non-fatal heroin overdose. Addiction. 2002;97(8):963–967.PubMedCrossRef
6.
go back to reference Hall W, Darke S. Trends in opiate overdose deaths in Australia 1979–1995. Drug Alcohol Depend. 1998;52(1):71–77.PubMedCrossRef Hall W, Darke S. Trends in opiate overdose deaths in Australia 1979–1995. Drug Alcohol Depend. 1998;52(1):71–77.PubMedCrossRef
7.
go back to reference Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. Addiction. 1996;91(3):405–411.PubMedCrossRef Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. Addiction. 1996;91(3):405–411.PubMedCrossRef
8.
go back to reference Burris S, Edlin B, Norland J. Legal aspects of providing naloxone to heroin users in the United States. Int J Drug Policy. 2001;12:237–248.CrossRef Burris S, Edlin B, Norland J. Legal aspects of providing naloxone to heroin users in the United States. Int J Drug Policy. 2001;12:237–248.CrossRef
9.
go back to reference Dettmer K, Saunders B, Strang J. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ. 2001;322:895–896.PubMedCrossRef Dettmer K, Saunders B, Strang J. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ. 2001;322:895–896.PubMedCrossRef
10.
go back to reference Seal KH, Downing M, Kral AH, et al. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay area. J Urban Health. June 1. 2003;80(2):291–301.PubMed Seal KH, Downing M, Kral AH, et al. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay area. J Urban Health. June 1. 2003;80(2):291–301.PubMed
11.
go back to reference McGregor C, Darke S, Ali R, Christie P. Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. Addiction. 1998;93(5):701–711.PubMedCrossRef McGregor C, Darke S, Ali R, Christie P. Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. Addiction. 1998;93(5):701–711.PubMedCrossRef
12.
go back to reference Darke S, Hall W. Heroin overdose: research and evidence-based intervention. J Urban Health. 2003;80(2):189–200.PubMed Darke S, Hall W. Heroin overdose: research and evidence-based intervention. J Urban Health. 2003;80(2):189–200.PubMed
13.
go back to reference Dietze P. Intranasal naloxone is an effective first line treatment for suspected opioid overdose in the prehospital setting. Paper presented at: 15th International Conference on the Reduction of Drug Related Harm; April 24, 2004; Melbourne, Australia. Dietze P. Intranasal naloxone is an effective first line treatment for suspected opioid overdose in the prehospital setting. Paper presented at: 15th International Conference on the Reduction of Drug Related Harm; April 24, 2004; Melbourne, Australia.
14.
go back to reference Food, Drug, and Cosmetic Act Sec. 503(b)(1). U.S.C. Vol 21; 1999. Food, Drug, and Cosmetic Act Sec. 503(b)(1). U.S.C. Vol 21; 1999.
15.
go back to reference Centers for Disease Control and P. Heroin overdose deaths—Multnomah County, Oregon, 1993–1999. MMWR — Morbidity & Mortality Weekly Report. 2000;49(28):633–636. Centers for Disease Control and P. Heroin overdose deaths—Multnomah County, Oregon, 1993–1999. MMWR — Morbidity & Mortality Weekly Report. 2000;49(28):633–636.
16.
go back to reference Strang J, Darke S, Hall W, Farrell M, Ali R. Heroin overdose: the case for take-home naloxone. BMJ. 1996;312(7044):1435–1436.PubMed Strang J, Darke S, Hall W, Farrell M, Ali R. Heroin overdose: the case for take-home naloxone. BMJ. 1996;312(7044):1435–1436.PubMed
17.
go back to reference Strang J, Powis B, Best D, et al. Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction. 1999;94(2):199–204.PubMedCrossRef Strang J, Powis B, Best D, et al. Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction. 1999;94(2):199–204.PubMedCrossRef
18.
go back to reference Sporer KA. Acute heroin overdose. Ann Intern Med. 1999;130(7):584–590.PubMed Sporer KA. Acute heroin overdose. Ann Intern Med. 1999;130(7):584–590.PubMed
19.
go back to reference Vilke GM, Buchanan J, Dunford JV, Chan TC. Are heroin overdose deaths related to patient release after pre-hospital treatment with naloxone? Prehosp Emerg Care. 1999;3(3):183–186.PubMedCrossRef Vilke GM, Buchanan J, Dunford JV, Chan TC. Are heroin overdose deaths related to patient release after pre-hospital treatment with naloxone? Prehosp Emerg Care. 1999;3(3):183–186.PubMedCrossRef
20.
go back to reference Bigg D. Opiate Overdose Prevention/Intervention Using Take-Home Naloxone. Paper presented at: 131st Annual Meeting of the American Public Health Association; November 18, 2003; San Francisco, California. Bigg D. Opiate Overdose Prevention/Intervention Using Take-Home Naloxone. Paper presented at: 131st Annual Meeting of the American Public Health Association; November 18, 2003; San Francisco, California.
21.
go back to reference Fiuty P. Naloxone Prescription to IDUs in New Mexico. Paper presented at: 131st Annual Meeting of the American Public Health Association; November 18, 2003; San Francisco, California. Fiuty P. Naloxone Prescription to IDUs in New Mexico. Paper presented at: 131st Annual Meeting of the American Public Health Association; November 18, 2003; San Francisco, California.
22.
go back to reference MacGillis A. City Overdose Deaths Fell by 12% Last Year: Ilicit Drug Toll of 261 in ’04 Was Lowest in 5 Years. Baltimore Sun. March 28, 2005;A:1. MacGillis A. City Overdose Deaths Fell by 12% Last Year: Ilicit Drug Toll of 261 in ’04 Was Lowest in 5 Years. Baltimore Sun. March 28, 2005;A:1.
23.
go back to reference Seal KH, Thawley R, Gee L, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. 2005;82(2):303–311.PubMed Seal KH, Thawley R, Gee L, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. 2005;82(2):303–311.PubMed
24.
go back to reference Sherman SG, Kral AH, Lorvick JA. Epidemiology of opiate overdose and response: a review of overdose prevention naloxone prescription interventions. Paper presented at: New York State Department of Health; April 18, 2005; New York City, New York. Sherman SG, Kral AH, Lorvick JA. Epidemiology of opiate overdose and response: a review of overdose prevention naloxone prescription interventions. Paper presented at: New York State Department of Health; April 18, 2005; New York City, New York.
25.
go back to reference Campana M. Overdose Mortality and Naloxone Distribution in Italy. Paper presented at: Preventing Heroin Overdose: Pragmatic Approaches; Jan. 13–14, 2000; Seattle, WA. Campana M. Overdose Mortality and Naloxone Distribution in Italy. Paper presented at: Preventing Heroin Overdose: Pragmatic Approaches; Jan. 13–14, 2000; Seattle, WA.
26.
go back to reference Finkelstein R, Ramos SE. Manual for Primary Care Providers: Effectively Caring for Active Substance Users. New York, NY: New York Academy of Medicine; 2003. Finkelstein R, Ramos SE. Manual for Primary Care Providers: Effectively Caring for Active Substance Users. New York, NY: New York Academy of Medicine; 2003.
27.
go back to reference National Center on Addiction and Substance Abuse. Missed opportunity: National survey of primary care physicians and patients on substance abuse. New York, NY: Columbia University; 2000. National Center on Addiction and Substance Abuse. Missed opportunity: National survey of primary care physicians and patients on substance abuse. New York, NY: Columbia University; 2000.
28.
go back to reference Ding L, Landon BE, Wilson IB, Wong MD, Shapiro MF, Cleary PD. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med. 2005;165:618–623.PubMedCrossRef Ding L, Landon BE, Wilson IB, Wong MD, Shapiro MF, Cleary PD. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med. 2005;165:618–623.PubMedCrossRef
29.
go back to reference Gastfriend DR. Physician substance abuse and recovery: what does it mean for physicians—and everyone else? JAMA. 2005;293(12):1513–1515.PubMedCrossRef Gastfriend DR. Physician substance abuse and recovery: what does it mean for physicians—and everyone else? JAMA. 2005;293(12):1513–1515.PubMedCrossRef
30.
go back to reference Heller D, McCoy K, Cunningham C. An invisible barrier to integrating HIV primary care with harm reduction services: philosophical clashes between the harm reduction and medical models. Public Health Rep. 2004;119(1):32–39.PubMed Heller D, McCoy K, Cunningham C. An invisible barrier to integrating HIV primary care with harm reduction services: philosophical clashes between the harm reduction and medical models. Public Health Rep. 2004;119(1):32–39.PubMed
31.
go back to reference Swenson-Britt E, Carrougher G, Martin BW, Brackley M. Project Hope: changing care delivery for the substance abuse patient. Clin Nurse Spec. 2000;14(2):92–100.PubMedCrossRef Swenson-Britt E, Carrougher G, Martin BW, Brackley M. Project Hope: changing care delivery for the substance abuse patient. Clin Nurse Spec. 2000;14(2):92–100.PubMedCrossRef
32.
go back to reference Rich JD, McKenzie M, Macalino GE, et al. A syringe prescription program to prevent infectious disease and improve health of injection drug users. J Urban Health. 2004;81(1):122–134.PubMed Rich JD, McKenzie M, Macalino GE, et al. A syringe prescription program to prevent infectious disease and improve health of injection drug users. J Urban Health. 2004;81(1):122–134.PubMed
33.
go back to reference Coffin PO, Blaney S, Fuller C, Vadnai L, Miller S, Vlahov D. Support for buprenorphine and methadone prescription to heroin-dependent patients among New York City physicians. Am J Drug Alcohol Abuse. 2006;32(1):1–6.PubMedCrossRef Coffin PO, Blaney S, Fuller C, Vadnai L, Miller S, Vlahov D. Support for buprenorphine and methadone prescription to heroin-dependent patients among New York City physicians. Am J Drug Alcohol Abuse. 2006;32(1):1–6.PubMedCrossRef
34.
go back to reference National Center for Health Statistics. Health, United States, 2003, with Chartbook on Trends in the Health of Americans. Hyattsville, Maryland: U.S. Department of Health and Human Services; 2003. National Center for Health Statistics. Health, United States, 2003, with Chartbook on Trends in the Health of Americans. Hyattsville, Maryland: U.S. Department of Health and Human Services; 2003.
35.
go back to reference Tobin KE, Gaasch WR, Clarke C, MacKenzie E, Latkin CA. Attitudes of emergency medical service providers toward naloxone distribution programs. J Urban Health. 2005;82(2):296–302.PubMed Tobin KE, Gaasch WR, Clarke C, MacKenzie E, Latkin CA. Attitudes of emergency medical service providers toward naloxone distribution programs. J Urban Health. 2005;82(2):296–302.PubMed
36.
go back to reference O’Connor PG, Selwyn PA, Schottenfeld RS. Medical progress: medical care for injection-drug users with human immunodeficiency virus infection. New Engl J Med. 1994;331:450–459.PubMedCrossRef O’Connor PG, Selwyn PA, Schottenfeld RS. Medical progress: medical care for injection-drug users with human immunodeficiency virus infection. New Engl J Med. 1994;331:450–459.PubMedCrossRef
37.
go back to reference Wartenberg AA. ‘Into whatever houses I enter’. HIV and injecting drug use. JAMA. 1994;271(2):151–152.PubMedCrossRef Wartenberg AA. ‘Into whatever houses I enter’. HIV and injecting drug use. JAMA. 1994;271(2):151–152.PubMedCrossRef
38.
go back to reference Weinrich M, Stuart M. Provision of methadone treatment in primary care medical practices: review of the Scottish experience and implications for U.S. Policy. JAMA. 2000;283:1343–1348.PubMedCrossRef Weinrich M, Stuart M. Provision of methadone treatment in primary care medical practices: review of the Scottish experience and implications for U.S. Policy. JAMA. 2000;283:1343–1348.PubMedCrossRef
39.
go back to reference Kendal EM. Effects of Attitudes on Delivery of Healthcare. The Community Health Nurse and Alcohol Problems. Rockford, Maryland: U.S. Department of Health; 1978. Kendal EM. Effects of Attitudes on Delivery of Healthcare. The Community Health Nurse and Alcohol Problems. Rockford, Maryland: U.S. Department of Health; 1978.
40.
go back to reference Leshner AI. Science-based views of drug addiction and its treatment. JAMA. 1999;282(14):1314–1316.PubMedCrossRef Leshner AI. Science-based views of drug addiction and its treatment. JAMA. 1999;282(14):1314–1316.PubMedCrossRef
41.
go back to reference Coffin PO, Fuller C, Vadnai L, Blaney S, Galea S, Vlahov D. Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. J Urban Health. 2003;80(2):288–290.PubMed Coffin PO, Fuller C, Vadnai L, Blaney S, Galea S, Vlahov D. Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. J Urban Health. 2003;80(2):288–290.PubMed
42.
go back to reference Limbert C, Lamb R. Doctors’ use of clinical guidelines: two applications of the Theory of Planned Behaviour. Psychol Health Med. 2002;7(3):301–310.CrossRef Limbert C, Lamb R. Doctors’ use of clinical guidelines: two applications of the Theory of Planned Behaviour. Psychol Health Med. 2002;7(3):301–310.CrossRef
43.
go back to reference Cundiff GW, Weidner AC, Visco AG, Bump RC, Addison WA. A survey of pessary use by members of the American Urogynecologic Society. Obstet Gynecol. 2000;95(6 Pt 1):931–935.PubMedCrossRef Cundiff GW, Weidner AC, Visco AG, Bump RC, Addison WA. A survey of pessary use by members of the American Urogynecologic Society. Obstet Gynecol. 2000;95(6 Pt 1):931–935.PubMedCrossRef
44.
go back to reference Urban N, Anderson GL, Tseng A. Effects on response rates and costs of stamps vs business reply in a mail survey of physicians. J Clin Epidemiol. 1993;46(5):455–459.PubMedCrossRef Urban N, Anderson GL, Tseng A. Effects on response rates and costs of stamps vs business reply in a mail survey of physicians. J Clin Epidemiol. 1993;46(5):455–459.PubMedCrossRef
45.
go back to reference Wolfe JM, Lein DY, Lenkoski K, Smithline HA. Analgesic administration to patients with an acute abdomen: a survey of emergency medicine physicians. Am J Emerg Med. 2000;18(3):250–253.PubMedCrossRef Wolfe JM, Lein DY, Lenkoski K, Smithline HA. Analgesic administration to patients with an acute abdomen: a survey of emergency medicine physicians. Am J Emerg Med. 2000;18(3):250–253.PubMedCrossRef
46.
go back to reference Gerbert B, Maguire BT, Bleecker T, Coates TJ, McPhee SJ. Primary care physicians and AIDS. Attitudinal and structural barriers to care. JAMA. 1991;266(20):2837–2842.PubMedCrossRef Gerbert B, Maguire BT, Bleecker T, Coates TJ, McPhee SJ. Primary care physicians and AIDS. Attitudinal and structural barriers to care. JAMA. 1991;266(20):2837–2842.PubMedCrossRef
47.
go back to reference Ritson EB. Alcohol, drugs and stigma. Int J Clin Pract. 1999;53:549–551.PubMed Ritson EB. Alcohol, drugs and stigma. Int J Clin Pract. 1999;53:549–551.PubMed
48.
go back to reference Coffin PO, Linas BP, Factor SH, Vlahov D. New York City pharmacists’ attitudes toward sale of needles/syringes to injection drug users before implementation of law expanding syringe access. J Urban Health. 2000;77(4):781–793.PubMedCrossRef Coffin PO, Linas BP, Factor SH, Vlahov D. New York City pharmacists’ attitudes toward sale of needles/syringes to injection drug users before implementation of law expanding syringe access. J Urban Health. 2000;77(4):781–793.PubMedCrossRef
49.
go back to reference Rich JD, Whitlock TL, Towe CW, et al. Prescribing syringes to prevent HIV: a survey of infectious disease and addiction medicine physicians in Rhode Island. Subst Use Misuse. 2001;36(5):535–550.PubMedCrossRef Rich JD, Whitlock TL, Towe CW, et al. Prescribing syringes to prevent HIV: a survey of infectious disease and addiction medicine physicians in Rhode Island. Subst Use Misuse. 2001;36(5):535–550.PubMedCrossRef
50.
go back to reference Hilton BA, Thompson R, Moore-Dempsey L, Janzen RG. Harm reduction theories and strategies for control of human immunodeficiency virus: a review of the literature. J Adv Nurs. 2001;33(3):357–370.PubMedCrossRef Hilton BA, Thompson R, Moore-Dempsey L, Janzen RG. Harm reduction theories and strategies for control of human immunodeficiency virus: a review of the literature. J Adv Nurs. 2001;33(3):357–370.PubMedCrossRef
51.
go back to reference Wodak A, Cooney A. Effectiveness of sterile needle and syringe programmes. Int J Drug Policy. 2005;16(Supp 1):S31–44.CrossRef Wodak A, Cooney A. Effectiveness of sterile needle and syringe programmes. Int J Drug Policy. 2005;16(Supp 1):S31–44.CrossRef
52.
go back to reference Klausner JD, Chaw JK. Patient-delivered therapy for chlamydia: putting research into practice. Sex Transm Dis. 2003;30(6):509–511.PubMedCrossRef Klausner JD, Chaw JK. Patient-delivered therapy for chlamydia: putting research into practice. Sex Transm Dis. 2003;30(6):509–511.PubMedCrossRef
53.
go back to reference New York State Assembly. An act to amend the public health law, in relation to opioid overdose prevention. McKinney’s Public Health Law. 2005–2006 Regular Sessions ed; 2006. New York State Assembly. An act to amend the public health law, in relation to opioid overdose prevention. McKinney’s Public Health Law. 2005–2006 Regular Sessions ed; 2006.
54.
go back to reference An Act Relating To Drugs; Authorizing And Releasing From Liability Persons Who Administer Opioid Antagonists; Releasing From Liability Licensed Health Care Professionals; Declaring An Emergency. New Mexico Statutes Annotated. Vol §§ 24-31-1 & -2; 2006. An Act Relating To Drugs; Authorizing And Releasing From Liability Persons Who Administer Opioid Antagonists; Releasing From Liability Licensed Health Care Professionals; Declaring An Emergency. New Mexico Statutes Annotated. Vol §§ 24-31-1 & -2; 2006.
Metadata
Title
Physicians’ Knowledge of and Willingness to Prescribe Naloxone to Reverse Accidental Opiate Overdose: Challenges and Opportunities
Authors
Leo Beletsky
Robin Ruthazer
Grace E. Macalino
Josiah D. Rich
Litjen Tan
Scott Burris
Publication date
01-01-2007
Publisher
Springer US
Published in
Journal of Urban Health / Issue 1/2007
Print ISSN: 1099-3460
Electronic ISSN: 1468-2869
DOI
https://doi.org/10.1007/s11524-006-9120-z

Other articles of this Issue 1/2007

Journal of Urban Health 1/2007 Go to the issue